---
schema_version: "secwatch.filing_event.v1"
accession: "0001434647-26-000009"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2026-03-09T23:59:59+00:00"
generated_at: "2026-05-15T17:36:05.907981+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zevra reports Q4 net revenue $34.1M, net income $12.2M; appoints Justin Renz as CFO

## Summary
- Q4 2025 net revenue $34.1M (+31% QoQ); net income $12.2M ($0.19 diluted EPS) vs. $(35.7)M loss in Q4 2024.
- FY 2025 net revenue $106.5M (MIPLYFFA $87.4M); net income $83.2M ($1.35 diluted EPS) vs. $(105.5)M loss in FY 2024.
- MIPLYFFA: 24 new prescription enrollment forms in Q4; 52 in 2025; 161 since launch; EU MAA under EMA review, 120-day questions received.
- Justin Renz appointed CFO effective March 9, 2026; base salary $520k, 45% target bonus, option grant of 300k shares vesting over 4 years.
- Cash, cash equivalents and securities $238.9M at year-end; 56.9M common shares outstanding.

## SEC filing metadata
- accession: 0001434647-26-000009
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2026-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000143464726000009/0001434647-26-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000143464726000009/zvra-20260304.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001434647-26-000009
- JSON: https://secwatch.observer/filing/0001434647-26-000009.json
- Plain text: https://secwatch.observer/filing/0001434647-26-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.